Table 1 Association of polymorphisms in circadian negative-feedback loop genes with overall survival in GC patients.

From: Genetic polymorphisms in circadian negative feedback regulation genes predict overall survival and response to chemotherapy in gastric cancer patients

Gene

SNP

Predicted function

Best Fitting Model

Training set

Validation set

Pooled analysis

HR a (95% CI)

P

Bootstrap b (P < 0.05)

HR a (95% CI)

P

HR a (95% CI)

P

CRY1

rs3809236

TFBS

Dominant

0.85 (0.64–1.09)

0.501

 

0.96 (0.75–1.21)

0.713

0.92 (0.69–1.28)

0.579

rs1056560

miRNA

Additive

0.72 (0.58–0.88)

0.021

96

0.74 (0.46–0.90)

0.023

0.65 (0.34–0.87)

0.001

CRY2

rs6798

TFBS

Dominant

0.88 (0.67–1.16)

0.422

 

0.97 (0.57–1.61)

0.869

0.95 (0.64–1.42)

0.287

rs2292910

miRNA

Dominant

0.95 (0.76–1.19)

0.652

 

1.12 (0.51–2.50)

0.725

1.07 (0.72–1.58)

0.695

PER1

rs2735611

Splicing

Dominant

0.87 (0.68–1.11)

0.275

 

0.92 (0.58–1.48)

0. 841

0.95 (0.65–1.57)

0.881

rs3027178

Splicing

Dominant

1.72 (1.19–2.35)

0.001

100

1.54 (1.07–1.98)

0.034

1.71 (1.25–2.34)

<0.001

PER2

rs2304669

Splicing

Dominant

0.92 (0.70–1.20)

0.403

 

1.12 (0.83–1.58)

0.612

1.16 (0.70–1.52)

0.326

rs934945

nsSNP

Dominant

0.76 (0.56–1.25)

0.482

 

0.91 (0.62–1.47)

0.862

0.89 (0.58–1.35)

0.933

PER3

rs228729

TFBS

Recessive

1.93 (1.31–2.85)

0.003

98

1.39 (0.82–1.97)

0.170

1.79 (1.29–2.93)

0.003

rs228669

Splicing

Dominant

1.15 (0.95–1.40)

0.391

 

1.14 (0.79–1.42)

0.506

1.19 (0.86–1.51)

0.275

rs2640908

Splicing

Recessive

1.44 (0.98–1.96)

0.076

 

1.31 (0.93–1.86)

0.127

1.27 (0.95–1.62)

0.113

rs172933

TFBS

Recessive

1.21 (0.74–1.44)

0.203

 

1.17 (0.64–1.51)

0.320

1.25 (0.98–1.57)

0.062

rs2859390

Splicing

Dominant

0.92 (0.72–1.18)

0.516

 

0.98 (0.73–1.31)

0.962

0.94 (0.69–1.43)

0.898

  1. Note: The significant values were shown in boldface (P < 0.05).
  2. HR indicates hazard ratio; CI, confidence interval; TFBS, transcription factor binding site.
  3. aAdjusted by age, sex, tumor site, tumor size, differentiation, TNM stage and chemotherapy where appropriate.
  4. bBootstrap analysis was performed using 100 replicates to determine statistics support.
Back to article page